Resveratrol, wine, and atherosclerosis

International Journal of Angiology

Volumn 21, Issue 1, 2012, Pages 7-17

  Prasad, Kailash ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Atherosclerosis; C reactive protein; Growth factors; Inflammatory mediators; Matrix metalloproteinase; Resveratrol; Serum lipids; Vascular smooth muscle cell proliferation; Wine

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALCOHOL; APOLIPOPROTEIN A1; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CHOLESTEROL; COLONY STIMULATING FACTOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; GROWTH FACTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 2; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PHENOL DERIVATIVE; PLATELET DERIVED GROWTH FACTOR; PTEROSTILBENE; RESVERATROL; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ALCOHOL CONSUMPTION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CAROTID ATHEROSCLEROSIS; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RED WINE; REMISSION; REVIEW; RISK FACTOR; RISK REDUCTION; SMOOTH MUSCLE FIBER; THROMBOCYTE AGGREGATION INHIBITION; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR SMOOTH MUSCLE; WINE;

EID: 84859201009     PISSN: 10611711     EISSN: 16155939     Source Type: Journal    
DOI: 10.1055/s-0032-1306417     Document Type: Review

References (160)

1. Statistics Canada. CAN SIM Table 102-0529: Deaths, by cause, Chapter IX: Diseases of the Circulatory System (100 to 199), age group and sex, Canada, annual (number), 2000-2006. Released May 4, 2010. Available at: http://dsp-psd.pwgsc.gc.ca/collections/collection-2010/statcan/84F0209X/ 8410209X2006000-eng.pdf. Accessed Jan 2012
2. Rosamond AW, Flegal K, Furie K, et al. Heart Disease and Stroke Statistics 2008 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Sub-committee. [Circulation AHA web site]. December 17, 2007. Available at: http://www.circ.ahajournals.org. Accessed March 10, 2009
3. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92(3):657-671
4. Nikkari ST, O'Brien KD, Ferguson M, et al. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation 1995;92(6):1393-1398
5. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995;92(6):1565-1569
6. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94(6):2493-2503 (Pubitemid 24379627)
7. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease-the Framingham Heart Study. Can J Cardiol 1988;4 (Suppl A):5A-10A
8. Ross R, Harker L. Hyperlipidemia and atherosclerosis. Science 1976;193(4258):1094-1100
9. Prasad K, Kalra J. Oxygen free radicals and hypercholesterolemic atherosclerosis: effect of vitamin E. Am Heart J 1993;125(4):958-973 (Pubitemid 23117326)
10. Prasad K. Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Circulation 1999;99(10):1355-1362 (Pubitemid 29129922)
11. Prasad K, Kalra J, Lee P. Oxygen free radicals asa mechanism of hypercholesterolemic atherosclerosis: effects of probucol. Int J Angiol 1994;3:100-112
12. Steinberg D. Antioxidants and atherosclerosis. Acurrent assessment. Circulation 1991;84(3):1420-1425
13. Steinberg D. Antioxidants in the prevention of human atherosclerosis. Summary of the proceedings of a National Heart, Lung, and Blood Institute Workshop: September 5-6, 1991, Bethesda, Maryland. Circulation 1992;85:2337-2344
14. Prasad K. Pathophysiology of atherosclerosis. In:Textbook of Angiology, JB Chang, R Olsen, K Prasad, BE Sumpio, eds. Springer-Verlag: New York Inc.; 2000;85-105
15. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: acomprehensive review of studies in mice. Cardiovasc Res 2008;79(3):360-376
16. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2(8618):983-986
17. Burke AP, Tracy RP, Kolodgie F, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation 2002;105(17):2019-2023 (Pubitemid 34465262)
18. Paul A, Ko KWS, Li L, et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficientmice. Circulation 2004;109(5):647-655 (Pubitemid 38198873)
19. Schmidt AM, Stern D. Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep 2000;2(5):430-436
20. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999;84(5):489-497 (Pubitemid 29138585)
21. Zhou Z,Wang K, Penn MS, et al. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation 2003;107(17):2238-2243 (Pubitemid 36547219)
22. Schwartz CJ, Valente AJ, Sprague EA. A modern view of atherogenesis. Am J Cardiol 1993;71(6, Suppl B):9B-14B
23. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992;339(8808): 1523-1526
24. Maclure M. Demonstration of deductive meta-analysis: ethanol intake and risk of myocardial infarction. Epidemiol Rev 1993;15 (2):328-351 (Pubitemid 24072633)
25. Rimm EB,Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ 1999; 319(7224):1523-1528
26. Scherr PA, LaCroix AZ,Wallace RB, et al. Light tomoderate alcohol consumption and mortality in the elderly. J Am Geriatr Soc 1992;40(7):651-657
27. Mukamal KJ, Kronmal RA, Mittleman MA, et al. Alcohol consumption and carotid atherosclerosis in older adults: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2003;23(12): 2252-2259 (Pubitemid 37532329)
28. Kiechl S, Willeit J, Egger G, Oberhollenzer M, Aichner F. Alcohol consumption and carotid atherosclerosis: evidence of dose-dependent atherogenic and antiatherogenic effects. Results from the Bruneck Study. Stroke 1994;25(8):1593-1598
29. Kauhanen J, Kaplan GA, Goldberg DE, Salonen R, Salonen JT. Pattern of alcohol drinking and progression of atherosclerosis. Arterioscler Thromb Vasc Biol 1999;19(12):3001-3006 (Pubitemid 30029830)
30. Demirovic J, Nabulsi A, Folsom AR, et al The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Alcohol consumption and ultrasonographically assessed carotid artery wall thickness and distensibility. Circulation 1993;88(6):2787-2793 (Pubitemid 23360206)
31. Ramprasath VR, Jones PJH. Anti-atherogenic effects of resveratrol. Eur J Clin Nutr 2010;64(7):660-668
32. Soleas GJ, Diamandis EP, Goldberg DM. Resveratrol: amolecule whose time has come? And gone?. Clin Biochem 1997;30(2):91-113 (Pubitemid 27180922)
33. Romero-Pérez AI, Ibern-Gómez M, Lamuela-Raventós RM, de La Torre-Boronat MC. Piceid, the major resveratrol derivative in grape juices. J Agric Food Chem 1999;47(4):1533-1536
34. Orallo F, Álvarez E, Camiña M, Leiro JM, Gómez E, Fernández P. The possible implication of trans-Resveratrol in the cardioprotective effects of long-termmoderatewine consumption.Mol Pharmacol 2002;61(2):294-302 (Pubitemid 34112803)
35. Gu X, Creasy L, Kester A, Zeece M. Capillary electrophoretic determination of resveratrol in wines. J Agric Food Chem 1999; 47(8):3223-3227 (Pubitemid 29422018)
36. Burns J, Yokota T, Ashihara H, Lean MEJ, Crozier A. Plant foods and herbal sources of resveratrol. J Agric Food Chem 2002;50 (11):3337-3340 (Pubitemid 34533643)
37. Sobolev VS, Cole RJ. trans-resveratrol content incommercial peanuts and peanut products. J Agric Food Chem 1999;47(4): 1435-1439 (Pubitemid 29217135)
38. Sato M, Suzuki Y, Okuda T, Yokotsuka K. Contents of resveratrol, piceid, and their isomers in commercially available wines made from grapes cultivated in Japan. Biosci Biotechnol Biochem1997; 61(11):1800-1805 (Pubitemid 127471767)
39. Feijóo O,Moreno A, Falqué E. Content of trans- and cis-resveratrol in Galician white and red wines. J Food Compost Anal 2008;21: 608-613
40. Ross R, Masuda J, Raines EW, et al. Localization of PDGF-B protein in macrophages in all phases of atherogenesis. Science 1990;248 (4958):1009-1012
41. Falcone DJ, McCaffrey TA, Haimovitz-Friedman A, Vergilio JA, Nicholson AC. Macrophage and foam cell release of matrix-bound growth factors. Role of plasminogen activation. J Biol Chem 1993;268(16):11951-11958 (Pubitemid 23168155)
42. Nilsson J, Sjölund M, Palmberg L, Thyberg J, Heldin CH. Arterial smooth muscle cells in primary culture produce a platelet-derived growth factor-like protein. Proc Natl Acad Sci U S A 1985;82(13):4418-4422 (Pubitemid 15234245)
43. DiCorleto PE. Cultured endothelial cells produce multiple growth factors for connective tissue cells. Exp Cell Res 1984;153(1):167-172 (Pubitemid 14088413)
44. Bowen-Pope DF, Dicorleto PE, Ross R. Interactions between the receptors for platelet-derived growth factor and epidermal growth factor. J Cell Biol 1983;96(3):679-683 (Pubitemid 13131328)
45. Sporn MB, Roberts AB, Wakefield LM, de Crombrugghe B. Some recent advances in the chemistry and biology of transforming growth factor-beta. J Cell Biol 1987;105(3):1039-1045 (Pubitemid 18029829)
46. FloreaniM, Napoli E, Quintieri L, Palatini P. Oral administration of trans-resveratrol to guinea pigs increases cardiac DT-diaphorase and catalase activities, and protects isolated atria from menadione toxicity. Life Sci 2003;72(24):2741-2750 (Pubitemid 36385079)
47. Jang JH, Surh YJ. Protective effects of resveratrol on hydrogen peroxide-induced apoptosis in rat pheochromocytoma (PC12) cells. Mutat Res 2001;496(1-2):181-190
48. Vivancos M, Moreno JJ. Effect of resveratrol, tyrosol and β-sitosterol on oxidised low-density lipoprotein-stimulated oxidative stress, arachidonic acid release and prostaglandin E2 synthesis by RAW 264.7 macrophages. Br J Nutr 2008;99(6):1199-1207
49. Rocha KKR, Souza GA, Ebaid GX, Seiva FRF, Cataneo AC, Novelli ELB. Resveratrol toxicity: effects on risk factors for atherosclerosis and hepatic oxidative stress in standard and high-fat diets. Food Chem Toxicol 2009;47(6):1362-1367
50. Li Y, Cao Z, Zhu H. Upregulation of endogenous antioxidants and phase 2 enzymes by the red wine polyphenol, resveratrol in cultured aortic smooth muscle cells leads to cytoprotection against oxidative and electrophilic stress. Pharmacol Res 2006;53(1):6-15 (Pubitemid 41619373)
51. Cao Z, Li Y. Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury. Eur J Pharmacol 2004; 489(1-2):39-48 (Pubitemid 38520069)
52. Leonard SS, Xia C, Jiang BH, et al. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem Biophys Res Commun 2003;309(4):1017-1026 (Pubitemid 37122632)
53. Soares DG, Andreazza AC, Salvador M. Sequestering ability of butylated hydroxytoluene, propyl gallate, resveratrol, and vitamins C and E against ABTS, DPPH, and hydroxyl free radicals in chemical and biological systems. J Agric Food Chem 2003; 51(4):1077-1080
54. Vinson JA, Dabbagh YA, Serry MM, Jang J. Plant flavonoids, especially tea flavonols, are powerful antioxidants using an in vitro oxidation model for heart disease. J Agric Food Chem 1995;43:2800-2802
55. Frankel EN, Waterhouse AL, Kinsella JE. Inhibition of human LDL oxidation by resveratrol. Lancet 1993;341(8852):1103-1104 (Pubitemid 23114451)
56. Mizutani K, Ikeda K, Kawai Y, Yamori Y. Protective effect of resveratrol on oxidative damage in male and female stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2001;28(1-2):55-59 (Pubitemid 32039558)
57. Frémont L, Belguendouz L, Delpal S. Antioxidant activity of resveratrol and alcohol-free wine polyphenols related to LDL oxidation and polyunsaturated fatty acids. Life Sci 1999;64 (26):2511-2521 (Pubitemid 29268427)
58. Juan SH, Cheng TH, Lin HC, Chu YL, Lee WS. Mechanism of concentration-dependent induction of heme oxygenase-1 by resveratrol in human aortic smooth muscle cells. Biochem Pharmacol 2005;69(1):41-48
59. Chow SE, Hshu YC, Wang JS, Chen JK. Resveratrol attenuates oxLDL-stimulated NADPH oxidase activity and protects endothelial cells from oxidative functional damages. J Appl Physiol 2007;102(4):1520-1527
60. Shigematsu S, Ishida S, Hara M, et al. Resveratrol, ared wine constituent polyphenol, prevents superoxide-dependent inflammatory responses induced by ischemia/reperfusion, platelet-activating factor, or oxidants. Free Radic Biol Med 2003;34(7):810-817 (Pubitemid 36316064)
61. Kohnen S, Franck T, Van Antwerpen P, et al. Resveratrol inhibits the activity of equine neutrophil myeloperoxidase by a direct interaction with the enzyme. J Agric Food Chem 2007;55(20): 8080-8087
62. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105(9):1135-1143 (Pubitemid 34212626)
63. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340(2):115-126
64. Leiro J, Álvarez E, Arranz JA, Laguna R, Uriarte E, Orallo F. Effects of cis-resveratrol on inflammatory murine macrophages: antioxidant activity and down-regulation of inflammatory genes. J Leukoc Biol 2004;75(6):1156-1165 (Pubitemid 38720660)
65. MacCarrone M, Lorenzon T, Guerrieri P, Agrò AF. Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur J Biochem 1999;265(1):27-34 (Pubitemid 29466009)
66. Bujanda L, García-Barcina M, Gutiérrez-de Juan V, et al. Effect of resveratrol on alcohol-induced mortality and liver lesions in mice. BMC Gastroenterol 2006;6:35-43
67. Boscolo P, del Signore A, Sabbioni E, et al. Effects of resveratrol on lymphocyte proliferation and cytokine release. Ann Clin Lab Sci 2003;33(2):226-231 (Pubitemid 36705934)
68. Gao X, Xu YX, Janakiraman N, Chapman RA, Gautam SC. Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. Biochem Pharmacol 2001;62(9):1299-1308 (Pubitemid 33055634)
69. Gao X, Deeb D, Media J, et al. Immunomodulatory activity of resveratrol: discrepant in vitro and in vivo immunological effects. Biochem Pharmacol 2003;66(12):2427-2435 (Pubitemid 37456749)
70. Wang MJ, Huang HM, Hsieh SJ, Jeng KCG, Kuo JS. Resveratrol inhibits interleukin-6 production in cortical mixed glial cells under hypoxia/hypoglycemia followed by reoxygenation. J Neuroimmunol 2001;112(1-2):28-34
71. Holmes-McNary M, Baldwin AS Jr. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res 2000;60(13):3477-3483 (Pubitemid 30482167)
72. Shen F, Chen SJ, Dong XJ, Zhong H, Li YT, Cheng GF. Suppression of IL-8 gene transcription by resveratrol in phorbol ester treated human monocytic cells. J Asian Nat Prod Res 2003;5(2):151-157 (Pubitemid 36566099)
73. Manna SK, Mukhopadhyay A, Aggarwal BB. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-κ B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 2000;164(12):6509-6519 (Pubitemid 30408836)
74. Venkatesan B, Valente AJ, Reddy VS, Siwik DA, Chandrasekar B. Resveratrol blocks interleukin-18-EMMPRIN cross-regulation and smooth muscle cell migration. Am J Physiol Heart Circ Physiol 2009;297(2):H874-H886
75. Zhu J, YongW,Wu X, et al. Anti-inflammatory effect of resveratrol on TNF-α-induced MCP-1 expression in adipocytes. Biochem Biophys Res Commun 2008;369(2):471-477
76. Cicha I, Regler M, Urschel K, Goppelt-Struebe M, Daniel WG, Garlichs CD. Resveratrol inhibits monocytic cell chemotaxis to MCP-1 and prevents spontaneous endothelial cell migration through Rho kinase-dependent mechanism. J Atheroscler Thromb 2011;18(12):1031-1042
77. Bertelli AA, Baccalini R, Battaglia E, Falchi M, Ferrero ME. Resveratrol inhibits TNF alpha-induced endothelial cell activation. Therapie 2001;56(5):613-616 (Pubitemid 34027039)
78. Ahn KS, Kim JH, Oh SR, Ryu SY, Lee HK. Inhibitory activity of stilbenes frommedicinal plants on the expression of cell adhesion molecules on THP1 cells. Planta Med 2000;66(7):641-644
79. Ferrero ME, Bertelli AE, Fulgenzi A, et al. Activity invitro of resveratrol on granulocyte and monocyte adhesion to endothelium. Am J Clin Nutr 1998;68(6):1208-1214 (Pubitemid 28550950)
80. Pendurthi UR, Rao LV. Resveratrol suppresses agonist-induced monocyte adhesion to cultured human endothelial cells. Thromb Res 2002;106(4-5):243-248 (Pubitemid 35248058)
81. Carluccio MA, Siculella L, Ancora MA, et al. Olive oil and red wine antioxidant polyphenols inhibit endothelial activation: antiatherogenic properties of Mediterranean diet phytochemicals. Arterioscler Thromb Vasc Biol 2003;23(4):622-629 (Pubitemid 36438075)
82. Ferrero ME, Bertelli AA, Pellegatta F, Fulgenzi A, Corsi MM, Bertelli A. Phytoalexin resveratrol (3-4′-5-trihydroxystilbene) modulates granulocyte andmonocyte endothelial adhesion. Transplant Proc 1998;30(8):4191-4193 (Pubitemid 29013202)
83. Leiro J, Arranz JA, Fraiz N, Sanmartín ML, Quezada E, Orallo F. Effect of cis-resveratrol on genes involved in nuclear factor kappa B signaling. Int Immunopharmacol 2005;5(2):393-406 (Pubitemid 40126362)
84. Park DW, Baek K, Kim JR, et al. Resveratrol inhibits foam cell formation via NADPH oxidase 1- mediated reactive oxygen species and monocyte chemotactic protein-1. Exp Mol Med 2009;41(3):171-179
85. Araim O, Ballantyne J, Waterhouse AL, Sumpio BE. Inhibition of vascular smooth muscle cell proliferation with red wine and red wine polyphenols. J Vasc Surg 2002;35(6):1226-1232 (Pubitemid 44718526)
86. Mnjoyan ZH, Fujise K. Profound negative regulatory effects by resveratrol on vascular smooth muscle cells: a role of p53-p21 (WAF1/CIP1) pathway. Biochem Biophys Res Commun 2003; 311(2):546-552 (Pubitemid 37340114)
87. Venkatesan B, Ghosh-Choudhury N, Das F, et al. Resveratrol inhibits PDGF receptor mitogenic signaling in mesangial cells: role of PTP1B. FASEB J 2008;22(10):3469-3482
88. Kim JW, Lim SC, Lee MY, et al. Inhibition of neointimal formation by trans-resveratrol: role of phosphatidyl inositol 3-kinase-dependent Nrf2 activation in heme oxygenase-1 induction. Mol Nutr Food Res 2010;54(10):1497- 1505
89. Park ES, Lim Y, Hong JT, et al. Pterostilbene, anatural dimethylated analog of resveratrol, inhibits rat aortic vascular smooth muscle cell proliferation by blocking Akt-dependent pathway. Vascul Pharmacol 2010;53(1-2):61-67
90. Lin MT, Yen ML, Lin CY, Kuo ML. Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. Mol Pharmacol 2003;64(5):1029-1036
91. Uchiyama T, Toda K, Takahashi S. Resveratrol inhibits angiogenic response of cultured endothelial F-2 cells to vascular endothelial growth factor, but not to basic fibroblast growth factor. Biol Pharm Bull 2010;33(7):1095-1100
92. Hu Y, Sun CY, Huang J, Hong L, Zhang L, Chu ZB. Antimyeloma effects of resveratrol through inhibition of angiogenesis. Chin Med J (Engl) 2007;120(19):1672-1677 (Pubitemid 47603955)
93. Chávez E, Reyes-Gordillo K, Segovia J, et al. Resveratrol prevents fibrosis, NF-kappaB activation and TGF-beta increases induced by chronic CCl4 treatment in rats. J Appl Toxicol 2008;28(1):35-43
94. Kim KH, Back JH, Zhu Y, et al. Resveratrol targets transforming growth factor-β2 signaling to block UV-induced tumor progression. J Invest Dermatol 2011;131(1):195-202
95. Vanamala J, Reddivari L, Radhakrishnan S, Tarver C. Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer 2010;10:238-251
96. Zou J, Huang Y, Chen Q, et al. Suppression of mitogenesis and regulation of cell cycle traverse by resveratrol in cultured smooth muscle cells. Int J Oncol 1999;15(4):647-651
97. Haider UG, Sorescu D, Griendling KK, Vollmar AM, Dirsch VM. Resveratrol increases serine15-phosphorylated but transcriptionally impaired p53 and induces a reversible DNA replication block in serum-activated vascular smooth muscle cells. Mol Pharmacol 2003;63(4):925-932 (Pubitemid 36369000)
98. Mizutani K, Ikeda K, Yamori Y. Resveratrol inhibits AGEs-induced proliferation and collagen synthesis activity in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Biochem Biophys Res Commun 2000;274(1):61-67 (Pubitemid 30496757)
99. Bertelli AA, Giovannini L, Giannessi D, et al. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int J Tissue React 1995;17(1):1-3
100. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, Goldberg DM. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 1995;235(2):207-219
101. Kirk RI, Deitch JA, Wu JM, Lerea KM. Resveratrol decreases early signaling events in washed platelets but has little effect on platelet in whole blood. Blood Cells Mol Dis 2000;26(2):144-150 (Pubitemid 30604894)
102. Wang Z, Huang Y, Zou J, Cao K, Xu Y, Wu JM. Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Int J Mol Med 2002;9(1):77-79
103. Newby AC, Zaltsman AB. Molecular mechanisms in intimal hyperplasia. J Pathol 2000;190(3):300-309
104. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340(2):115-126
105. Galis ZS, Johnson C, Godin D, et al. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res 2002; 91(9):852-859 (Pubitemid 35285084)
106. Cho A, Reidy MA. Matrix metalloproteinase-9 isnecessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ Res 2002;91(9):845-851 (Pubitemid 35285083)
107. Lee SJ, Kim MM. Resveratrol with antioxidant activity inhibits matrix metalloproteinase via modulation of SIRT1 in human fibrosarcoma cells. Life Sci 2011;88(11-12):465-472
108. Lee B, Moon SK. Resveratrol inhibits TNF-alpha-induced proliferation and matrix metalloproteinase expression in human vascular smooth muscle cells. J Nutr 2005;135(12):2767-2773 (Pubitemid 43156539)
109. Miura D, Miura Y, Yagasaki K. Hypolipidemic action of dietary resveratrol, a phytoalexin in grapes and red wine, in hepatomabearing rats. Life Sci 2003;73(11):1393-1400 (Pubitemid 36798126)
110. Zhu L, Luo X, Jin Z. Effect of resveratrol on serum and liver lipid profile and antioxidant activity in hyperlipidemia rats. Asian Aust J Anim Sci 2008;21:890-895 (Pubitemid 351762198)
111. Cho IJ, Ahn JY, Kim S, Choi MS, Ha TY. Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters. Biochem Biophys Res Commun 2008;367(1):190-194
112. Do GM, Kwon EY, Kim HJ, et al. Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. Biochem Biophys Res Commun 2008;374(1):55-59
113. Penumathsa SV, Thirunavukkarasu M, Koneru S, et al. Statin and resveratrol incombination induces cardioprotection against myocardial infarction in hypercholesterolemic rat. J Mol Cell Cardiol 2007;42(3):508-516 (Pubitemid 46349117)
114. Nihei T, Miura Y, Yagasaki K. Inhibitory effect of resveratrol on proteinuria, hypoalbuminemia and hyperlipidemia in nephritic rats. Life Sci 2001;68(25):2845-2852 (Pubitemid 32448890)
115. Ahn J, Cho I, Kim S, Kwon D, Ha T. Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. J Hepatol 2008;49(6):1019-1028
116. Rivera L, Morón R, Zarzuelo A, Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol 2009;77(6): 1053-1063
117. Turrens JF, Lariccia J, Nair MG. Resveratrol has noeffect on lipoprotein profile and does not prevent peroxidation of serum lipids in normal rats. Free Radic Res 1997;27(6):557-562 (Pubitemid 28051183)
118. De Castro M, Veiga APM, Pacheco MR. Plasma lipid profile of experimentally induced hyperlipidemic New Zealand white rabbits is not affected by resveratrol. J Appl Res 2009;9:18-22
119. Hurlimann J, Thorbecke GJ, Hochwald GM. The liver asthe site of C-reactive protein formation. J Exp Med 1966;123(2):365-378
120. Mackiewicz A, Speroff T, Ganapathi MK, Kushner I. Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. J Immunol 1991;146(9):3032-3037
121. Pasceri V, Cheng JS,Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531-2534 (Pubitemid 32521959)
122. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102(18):2165- 2168
123. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000;20(9):2094-2099
124. Venugopal SK, Devaraj S, Jialal I. Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 2005;14(1):33-37 (Pubitemid 40110697)
125. Verma S, Szmitko PE, Ridker PM. C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med 2005;2(1):29-36, quiz 58
126. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 1990; 65(3):168-172 (Pubitemid 20031251)
127. Rebuzzi AG, Quaranta G, Liuzzo G, et al. Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. AmJ Cardiol 1998;82(6):715-719
128. Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999;34(5): 1512-1521 (Pubitemid 29528666)
129. de Winter RJ, Koch KT, van Straalen JP, et al. C-reactive protein and coronary events following percutaneous coronary angioplasty. Am J Med 2003;115(2):85-90 (Pubitemid 37288834)
130. Kaur G, Rao LVM, Agrawal A, Pendurthi UR. Effect of wine phenolics on cytokine-induced C-reactive protein expression. J Thromb Haemost 2007;5(6):1309-1317 (Pubitemid 46902135)
131. Avellone G, Di Garbo V, Campisi D, et al. Effects of moderate Sicilian red wine consumption on inflammatory biomarkers of atherosclerosis. Eur J Clin Nutr 2006;60(1):41-47 (Pubitemid 43731073)
132. Schmidt AM, Stern D. Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep 2000;2(5):430-436
133. Sakaguchi T, Yan SF, Yan SD, et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003; 111(7):959-972 (Pubitemid 36397472)
134. McNair ED, Wells CR, Mabood Qureshi A, et al. Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention. Clin Cardiol 2010;33(11):678-685
135. Zhou Z,Wang K, Penn MS, et al. Receptor for AGE (RAGE)mediates neointimal formation in response to arterial injury. Circulation 2003;107(17):2238-2243 (Pubitemid 36547219)
136. Prasad K. Soluble receptor for advanced glycation end products (sRAGE) and cardiovascular disease. Int J Angiol 2006;15:57-68
137. Hofmann MA, Drury S, Fu C, et al. RAGE mediates anovel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999;97(7):889-901 (Pubitemid 29375048)
138. Reznikov LL, Waksman J, Azam T, et al. Effect of advanced glycation end products on endotoxin-induced TNF-alpha, IL-1beta and IL-8 in human peripheral blood mononuclear cells. Clin Nephrol 2004;61(5):324-336 (Pubitemid 38579018)
139. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994;269(13):9889-9897 (Pubitemid 24196599)
140. WautierMP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. AmJ Physiol Endocrinol Metab 2001;280(5):E685-E694
141. Yonekura H, Yamamoto Y, Sakurai S, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370(Pt 3):1097-1109 (Pubitemid 36399105)
142. Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 2006;13(17):1971-1978
143. Jing YH, Chen KH, Yang SH, Kuo PC, Chen JK. Resveratrol ameliorates vasculopathy in STZ-induced diabetic rats: role of AGE-RAGE signalling. Diabetes Metab Res Rev 2010;26(3):212-222
144. Zhang Y, Luo Z, Ma L, Xu Q, Yang Q, Si L. Resveratrol prevents the impairment of advanced glycosylation end products (AGE) on macrophage lipid homeostasis by suppressing the receptor for AGE via peroxisome proliferator-activated receptor gamma activation. Int J Mol Med 2010;25(5):729-734
145. Liu FC, Hung LF, Wu WL, et al. Chondroprotective effects and mechanisms of resveratrol in advanced glycation end products-stimulated chondrocytes. Arthritis Res Ther 2010;12(5): R167
146. Grønbaek M, Becker U, Johansen D, et al. Type of alcohol consumed and mortality from all causes, coronary heart disease, and cancer. Ann Intern Med 2000;133(6):411-419
147. Klatsky AL, Friedman GD, Armstrong MA, Kipp H. Wine, liquor, beer, and mortality. Am J Epidemiol 2003;158(6):585-595 (Pubitemid 37093234)
148. Renaud SC, Guéguen R, Siest G, Salamon R. Wine, beer, and mortality in middle-aged men from eastern France. Arch Intern Med 1999;159(16):1865-1870 (Pubitemid 29424706)
149. Hayek T, Fuhrman B, Vaya J, et al. Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Arterioscler Thromb Vasc Biol 1997;17(11):2744-2752 (Pubitemid 28016017)
150. Stocker R, O'Halloran RA. Dealcoholized red wine decreases atherosclerosis in apolipoprotein E gene-deficient mice independently of inhibition of lipid peroxidation in the artery wall. Am J Clin Nutr 2004;79(1):123-130 (Pubitemid 41132073)
151. Klurfeld DM, Kritchevsky DM. Differential effects of alcoholic beverages on experimental atherosclerosis in rabbits. Exp Mol Pathol 1981;34(1):62-71 (Pubitemid 11134210)
152. da Luz PL, Serrano Júnior CV, Chacra AP, et al. The effect of red wine on experimental atherosclerosis: lipid-independent protection. Exp Mol Pathol 1999;65(3):150-159 (Pubitemid 29187390)
153. Abbey M, Kerry NL. Flavonoids and their effects on LDL oxidation. Proc
154. Wang Z, Zou J, Cao K, Hsieh TC, Huang Y, Wu JM. Dealcoholized red wine containing known amounts of resveratrol suppresses atherosclerosis in hypercholesterolemic rabbits without affecting plasma lipid levels. Int J Mol Med 2005;16(4):533-540
155. Vinson JA, Teufel K, Wu N. Red wine, dealcoholized red wine, and especially grape juice, inhibit atherosclerosis in a hamster model. Atherosclerosis 2001;156(1):67-72 (Pubitemid 32429596)
156. Do GM, Kwon EY, Kim HJ, et al. Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. Biochem Biophys Res Commun 2008;374(1):55-59
157. Fukao H, Ijiri Y, Miura M, et al. Effect of trans-resveratrol on the thrombogenicity and atherogenicity in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Blood Coagul Fibrinolysis 2004;15(6):441-446 (Pubitemid 39180227)
158. Castro M, Pacheco MMR, Machado MRF. Morphology of aortic arch in rabbits with atherosclerosis treated with resveratrol. Int J Appl Res Vet Med 2009;7:190-195
159. Wilson T, Knight TJ, Beitz DC, Lewis DS, Engen RL. Resveratrol promotes atherosclerosis in hypercholesterolemic rabbits. Life Sci 1996;59:15-21
160. Hai O, Anwar K, Wirkowski PA, Voloshyna I, Carsons S, Reiss AB. Resveratrol exhibits anti-atherogenic properties by facilitating cholesterol efflux from THP-1 human monocytes/macrophages. Presented at Eastern Regional Meeting on American Federal for Medical Research, Washington, DC, April 6, 2010. Available at: www.afmr.org/abstracts/2010Eastern-Program.cgi